Category: by institution

High-profile book on North Korea earns 52 corrections

The author of a high-profile book about the history of North Korea is issuing 52 corrections to the next edition, scheduled to appear this spring. The changes follow heavy criticism of the book, alleging it contained material not supported by the list of references.

Last month, author Charles Armstrong, a professor at Columbia University, announced on his website that he was issuing the changes after reviewing the book in detail, especially the footnotes. He writes:

Continue reading High-profile book on North Korea earns 52 corrections

Prominent Harvard researcher issues second retraction, again citing duplication

The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.

In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”

Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:

Continue reading Prominent Harvard researcher issues second retraction, again citing duplication

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Karolinska requests retraction of 2014 Macchiarini paper

Paolo Macchiarini

It has been a tough couple of years for surgeon Paolo Macchiarini, once lauded for pioneering a groundbreaking procedure to transplant tracheas.

After a series of documentaries prompted his former employer, Karolinska Institutet (KI), to reopen a misconduct investigation against him, KI has today released one verdict regarding a 2014 Nature Communications paper: guilty.

KI said it is contacting the journal to request a retraction of the paper, which has already been flagged with an expression of concern.

Here’s more from a release from the institution: Continue reading Karolinska requests retraction of 2014 Macchiarini paper

Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

John Thomas
John Thomas

This summer, Columbia University signed a settlement agreement with the U.S. government over a case filed under the False Claims Act (FCA), which enables whistleblowers to sue institutions on behalf of the government. Although this may seem like one of the many legal issues facing academic science recently, this case merits a closer look, says John R. Thomas, Jr., an attorney with Gentry Locke who represents whistleblowers in a variety of FCA cases – including a potentially landmark case against Duke University that we covered for Science. Thomas – who also authored a three-part Retraction Watch primer on how to file an FCA suit (“So You Want to Be a Whistleblower?” Part One, Part Two, Part Three) – tells us what we need to know about this latest FCA verdict.

As readers of Retraction Watch are unfortunately well aware, dishonesty in research comes in many forms. While we often focus on dishonesty in research itself, scientists and institutions may also defraud the government through a variety of administrative avenues, such as effort reporting (accounting for researcher time), improper cost accounting, and inflated facilities and administrative (F&A) costs.

We saw an example of this in July, when Continue reading Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.

Paul S. Thaler
Paul S. Thaler
Richard Goldstein
Richard Goldstein

Retraction Watch readers may recall the case of Piero Anversa and Annarosa Leri, both formerly of Harvard and the Brigham & Women’s Hospital in Boston. The pair — which has had their work subjected to a retraction, expression of concern, and correction — sued their former employers in 2014 for costing them job offers after the institutions notified journals, triggering notices. A judge dismissed the case a year ago, saying that Anversa and Leri had to try other administrative remedies before bringing suit.

But Anversa and Leri appealed, and last week, a court denied that appeal. (See the judge’s decision — which begins by quoting Ecclesiastes and includes the delicious word “gallimaufry” — here.) We spoke by email to two attorneys — Richard Goldstein, who represented the scientist in Bois v. HHS, the first case to overturn a funding ban by the Office of Research Integrity (ORI), and Paul Thaler, who has represented scientists involved in misconduct proceedings for more than 25 years — about the case, and what it could mean for similar lawsuits.

Retraction Watch: The decision seems to stop Anversa and Leri from continuing their suit against Harvard and the Brigham, but also acknowledges some of the scientists’ concerns as legitimate. How would you summarize the findings and their implications? Continue reading Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.

Cancer researcher logs 5th retraction

Journal of Mammary Gland Biology and NeoplasiaA cancer researcher has added a fifth retraction to his name — but the notice doesn’t mention any problems with the paper itself. 

Rather, the Journal of Mammary Gland Biology and Neoplasia decided to retract the paper because it referenced other papers that had been retracted as a result of data manipulation.

The notice doesn’t specify which references were problematic, but the list includes three papers that are now retracted; all three include Scott Valastyan (the sole author of the newly retracted paper) as first author, and two list Robert Weinberg, his former supervisor and prominent cancer researcher, as last author.

Continue reading Cancer researcher logs 5th retraction

Coptic cop-out? Religion journal won’t pull paper based on bogus ‘gospel’

HTR107_02What the Harvard Theological Review giveth, it evidently will not taketh away.

The venerable publication about religious matters is refusing to retract a 2014 article by a noted scholar of early Christianity despite evidence that the article — about Jesus’s wife — was based on a forgery.

The paper, by Harvard theologian Karen King, described a Coptic papyrus called “The Gospel of Jesus’s Wife,” which, among other things, includes language that suggests Christ was married: Continue reading Coptic cop-out? Religion journal won’t pull paper based on bogus ‘gospel’

Retractions aren’t enough: Why science has bigger problems

Andrew Gelman
Andrew Gelman

Scientific fraud isn’t what keeps Andrew Gelman, a professor of statistics at Columbia University in New York, up at night. Rather, it’s the sheer number of unreliable studies — uncorrected, unretracted — that have littered the literature. He tells us more, below.

Whatever the vast majority of retractions are, they’re a tiny fraction of the number of papers that are just wrong — by which I mean they present no good empirical evidence for their claims.

I’ve personally had to correct two of my published articles.   Continue reading Retractions aren’t enough: Why science has bigger problems

Singapore investigation leads to another retraction, correction for Harvard research fellow

Screen Shot 2016-03-25 at 8.12.49 AM

After an investigation found evidence of misconduct, a biologist has issued a third retraction.

Sudarsanareddy Lokireddy — now a research fellow at Harvard Medical School — “admitted falsification,” a Research Integrity Officer at Nanyang Technological University in Singapore told us in December. According to The Scientist, another journal has also published a correction that the authors had requested earlier.

The newly retracted paper is “Myostatin is a novel tumoral factor that induces cancer cachexia,” published in Biochemical Journal and cited 40 times, according to Thomson Reuters Web of Science. Here’s the retraction note: